Nabriva Therapeutics plc
NBRVF
$0.0001
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -38.64% | 61.81% | -97.83% | -3.97% | 6.30% |
| Total Depreciation and Amortization | -14.29% | -16.00% | -32.43% | -51.95% | -1.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 471.30% | -69.32% | 609.08% | 254.80% | -86.02% |
| Change in Net Operating Assets | 180.29% | -89.84% | 256.91% | 310.55% | 58.87% |
| Cash from Operations | 109.10% | -245.72% | 73.69% | 52.63% | 17.84% |
| Capital Expenditure | 100.00% | 66.67% | 91.26% | -60.94% | -82.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 300.00% | 98.08% | -5,100.00% |
| Cash from Investing | -1,566.67% | 57.14% | 93.27% | 10.34% | -222.22% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -386.27% | -2.46% | -2.63% | -- |
| Issuance of Common Stock | -- | -- | -82.44% | 170.16% | -64.21% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | 102.44% | 50.00% | 87.27% | -1,363.64% |
| Cash from Financing | 100.00% | -636.27% | -159.48% | 239.90% | -136.10% |
| Foreign Exchange rate Adjustments | 11.19% | -338.33% | 127.03% | -246.05% | 192.68% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 103.15% | -375.84% | 58.65% | 60.89% | 0.58% |